BNP levels predict outcome in pediatric heart failure patients post hoc analysis of the Pediatric Carvedilol Trial

Circulation: Heart Failure

Volumn 3, Issue 5, 2010, Pages 606-611

  Auerbach, Scott R ^a   Richmond, Marc E ^a   Lamour, Jacqueline M ^b   Blume, Elizabeth D ^c   Addonizio, Linda J ^a   Shaddy, Robert E ^d   Mahony, Lynn ^e   Pahl, Elfriede ^f   Hsu, Daphne T ^b  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

^d CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^f NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Cardiomyopathy; Heart failure; Natriuretic peptides; Pediatrics

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; CARVEDILOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; CARBAZOLE DERIVATIVE; PROPANOLAMINE DERIVATIVE;

ARTICLE; CARDIOMYOPATHY; CHILD; CONGENITAL HEART DISEASE; CONTROLLED STUDY; DEATH; DIAGNOSTIC VALUE; DISEASE SEVERITY; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART TRANSPLANTATION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PEDIATRICS; POST HOC ANALYSIS; PRESCHOOL CHILD; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SCHOOL CHILD; SENSITIVITY AND SPECIFICITY; AGE; BLOOD; CHI SQUARE DISTRIBUTION; CONGENITAL HEART MALFORMATION; INFANT; MULTICENTER STUDY; NONPARAMETRIC TEST; PREDICTION AND FORECASTING; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; AGE FACTORS; BIOLOGICAL MARKERS; CARBAZOLES; CARDIOMYOPATHIES; CHI-SQUARE DISTRIBUTION; CHILD; CHILD, PRESCHOOL; FEMALE; HEART DEFECTS, CONGENITAL; HEART FAILURE; HUMANS; INFANT; MALE; MULTICENTER STUDIES AS TOPIC; NATRIURETIC PEPTIDE, BRAIN; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPANOLAMINES; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SENSITIVITY AND SPECIFICITY; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 77957922082     PISSN: 19413289     EISSN: 19413297     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.109.906875     Document Type: Article

References (25)

1. Yasue H, Yoshimura M, Sumida H, Kikuta K, Kugiyama K, Jougasaki M, Ogawa H, Okumura K, Mukoyama M, Nakao K. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation. 1994;90:195-203. (Pubitemid 24203680)
2. Yoshimura M, Yasue H, Okumura K, Ogawa H, Jougasaki M, Mukoyama M, Nakao K, Imura H. Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure. Circulation. 1993;87:464-469. (Pubitemid 23040916)
3. Sawada Y, Suda M, Yokoyama H, Kanda T, Sakamaki T, Tanaka S, Nagai R, Abe S, Takeuchi T. Stretch-induced hypertrophic growth of cardiocytes and processing of brain-type natriuretic peptide are controlled by proprotein-processing endoprotease furin. J Biol Chem. 1997;272:20545-20554. (Pubitemid 27355612)
4. Sudoh T, Kangawa K, Minamino N, Matsuo H. A new natriuretic peptide in porcine brain. Nature. 1988;332:78-81. (Pubitemid 18083551)
5. Yan W, Wu F, Morser J, Wu Q. Corin, a transmembrane cardiac serine protease, acts as a pro-atrial natriuretic peptide-converting enzyme. Proc Natl Acad Sci USA. 2000;97:8525-8529. (Pubitemid 30639706)
6. Harrison A, Morrison LK, Krishnaswamy P, Kazanegra R, Clopton P, Dao Q, Hlavin P, Maisel AS. B-type natriuretic peptide predicts future cardiac events in patients presenting to the emergency department with dyspnea. Ann Emerg Med. 2002;39:131-138. (Pubitemid 34118942)
7. Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, Omland T, Storrow AB, Abraham WT, Wu AH, Clopton P, Steg PG, Westheim A, Knudsen CW, Perez A, Kazanegra R, Herrmann HC, McCullough PA, Breathing Not Properly Multinational Study I. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002;347:161-167. (Pubitemid 34764819)
8. Schaufelberger M, Swedberg K, Koster M, Rosen M, Rosengren A. Decreasing one-year mortality and hospitalization rates for heart failure in Sweden: data from the Swedish Hospital Discharge Registry 1988 to 2000. Eur Heart J. 2004;25:300-307. (Pubitemid 38295438)
9. Lin NC, Landt ML, Trinkaus KM, Balzer DT, Kort HW, Canter CE. Relation of age, severity of illness, and hemodynamics with brain natriuretic peptide levels in patients <20 years of age with heart disease. Am J Cardiol. 2005;96:847-850. (Pubitemid 41317663)
10. Wilson Tang WH, Francis GS, Morrow DA, Newby LK, Cannon CP, Jesse RL, Storrow AB, Christenson RH, Committee M, Christenson RH, Apple FS, Cannon CP, Francis GS, Jesse RL, Morrow DA, Newby LK, Ravkilde J, Storrow AB, Tang WHW, Wu AHB. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: clinical utilization of cardiac biomarker testing in heart failure. Circulation. 2007;116: e99-e109. (Pubitemid 47450268)
11. Law YM, Keller BB, Feingold BM, Boyle GJ. Usefulness of plasma B-type natriuretic peptide to identify ventricular dysfunction in pediatric and adult patients with congenital heart disease. Am J Cardiol. 2005;95:474-478. (Pubitemid 40247541)
12. Suda K, Matsumura M, Matsumoto M. Clinical implication of plasma natriuretic peptides in children with ventricular septal defect. Pediatr Int. 2003;45:249-254. (Pubitemid 36995093)
13. Ohuchi H, Takasugi H, Ohashi H, Okada Y, Yamada O, Ono Y, Yagihara T, Echigo S. Stratification of pediatric heart failure on the basis of neurohormonal and cardiac autonomic nervous activities in patients with congenital heart disease. Circulation. 2003;108:2368-2376. (Pubitemid 37413544)
14. Mir TS, Marohn S, Laer S, Eiselt M, Grollmus O, Weil J. Plasma concentrations of N-terminal pro-brain natriuretic peptide in control children from the neonatal to adolescent period and in children with congestive heart failure. Pediatrics. 2002;110: e76.
15. Price JF, Thomas AK, Grenier M, Eidem BW, Smith EOB, Denfield SW, Towbin JA, Dreyer WJ. B-type natriuretic peptide predicts adverse cardiovascular events in pediatric outpatients with chronic left ventricular systolic dysfunction. Circulation. 2006;114:1063-1069. (Pubitemid 44358883)
16. Shaddy RE, Boucek MM, Hsu DT, Boucek RJ, Canter CE, Mahony L, Ross RD, Pahl E, Blume ED, Dodd DA, Rosenthal DN, Burr J, LaSalle B, Holubkov R, Lukas MA, Tani LY. Carvedilol for children and adolescents with heart failure: a randomized controlled trial. JAMA. 2007;298:1171-1179. (Pubitemid 47403103)
17. Shaddy RE, Curtin EL, Sower B, Tani LY, Burr J, LaSalle B, Boucek MM, Mahony L, Hsu DT, Pahl E, Burch GH, Schlencker-Herceg R. The Pediatric Randomized Carvedilol Trial in Children with Heart Failure: rationale and design. Am Heart J. 2002;144:383-389.
18. Daubeney PE, Blackstone EH, Weintraub RG, Slavik Z, Scanlon J, Webber SA. Relationship of the dimension of cardiac structures to body size: an echocardiographic study in normal infants and children. Cardiol Young. 1999;9:402-410.
19. Nishii M, Inomata T, Takehana H, Naruke T, Yanagisawa T, Moriguchi M, Takeda S, Izumi T. Prognostic utility of B-type natriuretic peptide assessment in stable low-risk outpatients with nonischemic cardiomyopathy after decompensated heart failure. J Am Coll Cardiol. 2008;51:2329-2335. (Pubitemid 351783361)
20. Koch A, Singer H. Normal values of B type natriuretic peptide in infants, children, and adolescents. Heart (British Cardiac Society). 2003;89:875-878. (Pubitemid 36920810)
21. Koch AM, Zink S, Singer H, Dittrich S. B-type natriuretic peptide levels in patients with functionally univentricular hearts after total cavopulmonary connection. Eur J Heart Fail. 2008;10:60-62.
22. Olivier M, O'Leary PW, Pankratz VS, Lohse CM, Walsh BE, Tajik AJ, Seward JB. Serial Doppler assessment of diastolic function before and after the Fontan operation. J Am Soc Echocardiogr. 2003;16:1136-1143. (Pubitemid 37371657)
23. Senzaki H, Masutani S, Ishido H, Taketazu M, Kobayashi T, Sasaki N, Asano H, Katogi T, Kyo S, Yokote Y. Cardiac rest and reserve function in patients with Fontan circulation. J Am Coll Cardiol. 2006;47:2528-2535. (Pubitemid 43866371)
24. Towbin JA, Lowe AM, Colan SD, Sleeper LA, Orav EJ, Clunie S, Messere J, Cox GF, Lurie PR, Hsu D, Canter C, Wilkinson JD, Lipshultz SE. Incidence, causes, and outcomes of dilated cardiomyopathy in children. JAMA. 2006;296:1867-1876. (Pubitemid 44596196)
25. Bettencourt P, Azevedo A, Pimenta J, Frioes F, Ferreira S, Ferreira A. N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation. 2004;110:2168-2174. (Pubitemid 39372496)